Repository logo
 
Publication

Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study

2018-08-03Journal article Open access
Simple item page
dc.contributor.authorSoeiro, C.
dc.contributor.authorGonçalves, C.
dc.contributor.authorMarques, M.
dc.contributor.authorMéndez, M.
dc.contributor.authorTavares, A.
dc.contributor.authorHorta, A.
dc.contributor.authorSarmento-Castro, R.
dc.date.accessioned2019-07-18T09:32:59Z
dc.date.available2019-07-18T09:32:59Z
dc.date.issued2018-08-03
dc.description.abstractINTRODUCTION: Concomitant use of ledipasvir and boosted protease inhibitors (PIs) may increase the risk of tenofovir (TDF) nephrotoxicity, since both these drugs increase TDF levels. Our aim was to evaluate glomerular filtration rate (eGFR) evolution during HCV treatment with sofosbuvir/ledipasvir (SOF/LDV) in HCV/HIV coinfected patients, according to their antiretroviral treatment (ARV). METHODS: Observational prospective study of HCV/HIV coinfected patients treated with SOF/LDV. eGFR evolution was evaluated during and 12 weeks after HCV treatment. Patients were categorized in three groups based on ARV regimen: non TDF, non-boosted TDF and TDF + boosted PI. RESULTS: We included 273 patients: 145 were receiving a non-TDF regimen, 78 a non-boosted TDF scheme and 50 were receiving TDF + boosted PI. We observed a statistically significant decrease in eGFR during treatment in all groups (non TDF p = 0.03, 95%CI [0.23-3.86], non-boosted TDF p < 0.01, 95%CI [3.36-7.44], TDF + PI p = 0.01, 95%CI [1.09-7.53]). The decrease was more pronounced in those receiving unboosted TDF (- 5.40 ml/min/1.73m2), but differences in eGFR decrease between the three groups were small and not statistically different (p = 0.06). eGFR decrease was greater in patients treated for 24 weeks (p = 0.009) and in cirrhotic patients (p = 0.036). At the end of follow up a recovery of eGFR was observed in all groups. CONCLUSION: We observed a significant decrease in eGFR during treatment in all study groups, that was small and reversible after SOF/LDV discontinuation. TDF was not associated with an increase in renal toxicity.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationBMC Infect Dis. 2018 Aug 3;18(1):364.pt_PT
dc.identifier.doi10.1186/s12879-018-3278-3pt_PT
dc.identifier.issn1471-2334
dc.identifier.urihttp://hdl.handle.net/10400.16/2272
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherBMCpt_PT
dc.relation.publisherversionhttps://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-018-3278-3pt_PT
dc.subjectCo-infection HIV/HCVpt_PT
dc.subjectDrug-drug interactionspt_PT
dc.subjectHCV treatmentpt_PT
dc.subjectProtease inhibitorpt_PT
dc.subjectRenal toxicitypt_PT
dc.subjectSofosbuvir/ledipasvirpt_PT
dc.subjectTenofovirpt_PT
dc.titleGlomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective studypt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceEnglandpt_PT
oaire.citation.issue1pt_PT
oaire.citation.startPage364pt_PT
oaire.citation.titleBMC Infectious Diseasespt_PT
oaire.citation.volume18pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Glomerular filtration rate change during chronic hepatitis C treatment.pdf
Size:
629.36 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.35 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

SINF - Artigos publicados em revistas indexadas na Pubmed/Medline